Skip to main content

Idiopathic Pulmonary Fibrosis clinical trials at UC Irvine

3 research studies open to eligible people

Showing trials for
  • BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis

    open to eligible people ages 40 years and up

    The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986278 in participants with Idiopathic Pulmonary Fibrosis.

    Orange, California and other locations

  • Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis

    open to eligible people ages 40 years and up

    Study RIN-PF-301 is designed to evaluate the superiority of inhaled treprostinil against placebo for the change in absolute forced vital capacity (FVC) from baseline to Week 52.

    Orange, California and other locations

  • TTI-101 in Participants With Idiopathic Pulmonary Fibrosis

    open to eligible people ages 40 years and up

    The primary objective of this study is to evaluate the safety and tolerability of oral daily administration of TTI-101 over a 12-week treatment duration in participants with idiopathic pulmonary fibrosis (IPF).

    Orange, California and other locations

Our lead scientists for Idiopathic Pulmonary Fibrosis research studies include .

Last updated: